Kevin Norrett - 21 Jan 2026 Form 4 Insider Report for SOLENO THERAPEUTICS INC (SLNO)

Reporting relationship: Chief Business Officer
Issuer ticker: SLNO
Reported as of: 21 Jan 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 23 Jan 2026, 18:07:08 UTC
Prior SEC filing: 19 Nov 2025
Next SEC filing: 18 May 2026
Source filing: View source filing
Reporting owner signature: /s/ Anish Bhatnagar, Attorney-in-Fact

Key filing fact

Kevin Norrett filed Form 4 for SOLENO THERAPEUTICS INC (SLNO) on 23 Jan 2026.

Key facts

This page summarizes Kevin Norrett's Form 4 filing for SOLENO THERAPEUTICS INC (SLNO).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 23 Jan 2026, 18:07.

Change

Previous filing in this sequence was filed on 19 Nov 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001819690 Primary reporting owner

Norrett Kevin

Relationship: Chief Business Officer
Address: 100 MARINE PARKWAY, SUITE 400, REDWOOD CITY
Signature: /s/ Anish Bhatnagar, Attorney-in-Fact
Signature date: 23 Jan 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

SLNO transaction

Common Stock

Award

Transaction value: $0
Shares: +3,500
Change %: +24%
Price: $0.000000
Shares after: 17,786
Date: 21 Jan 2026
Ownership: Direct
Footnotes: F1, F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

SLNO transaction Derivative

Employee stock option (right to buy)

Award

Transaction value: $0
Shares: +4,000
Change %
Price: $0.000000
Shares after: 4,000
Date: 21 Jan 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 4,000
Exercise price: $43.65
Footnotes: F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

These securities are restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Common Stock. 100% of the RSUs shall vest on December 15, 2027, subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2014 Equity Incentive Plan) through such date.

Footnote F2

These securities are RSUs. Each RSU represents a contingent right to receive one share of Common Stock, subject to the applicable vesting schedule and conditions of each RSU.

Footnote F3

1/48th of the shares subject to the option shall vest on February 1, 2026 and each one-month anniversary thereafter, subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2014 Equity Incentive Plan) through each such date.